Veliparib (Synonyms: ABT-888)

Name: Veliparib
Brand: MedChemExpress
SKU: HY-10129
Rating: 5.0 (49 reviews)

Cat. No.: HY-10129 Pureza: 99.77%: Ficha de datos
COA

SDS
Instrucciones de manejo
FAQs
Technical Support

Veliparib (ABT-888) is a potent PARP inhibitor, inhibiting PARP1 and PARP2 with K_is of 5.2 and 2.9 nM, respectively.

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS : 912444-00-9

Tamaño	Stock	Cantidad

Muestra gratis (0.1 - 0.2 mg)	Solicite ahora
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	En stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	En stock	Estimated Time of Arrival: December 31
Solid
5 mg	En stock	Estimated Time of Arrival: December 31
10 mg	En stock	Estimated Time of Arrival: December 31
25 mg	En stock	Estimated Time of Arrival: December 31
50 mg	En stock	Estimated Time of Arrival: December 31
100 mg	En stock	Estimated Time of Arrival: December 31
200 mg	En stock	Estimated Time of Arrival: December 31
500 mg	Obtener un presupuesto
1 g	Obtener un presupuesto

or Consulta para venta a granel

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 49 publication(s) in Google Scholar

Other Forms of Veliparib:

Veliparib dihydrochloride In-stock
Veliparib (Standard) Obtener un presupuesto

49 Publications Citing Use of MCE Veliparib

Cell Proliferation/Viability Assay

RT-PCR

Bio/Physico-chemical Assay

: Veliparib purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jul 16:e15585. [Abstract]; Veliparib (0-100 μM; 72 h). Dose‐response curves for Veliparib after 72 h of treatment in MDA‐MB‐468 cells comparing empty vector control (Control) and ARID1B OE cells.

: Veliparib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Jun 24;12(1):3931. [Abstract]; Veliparib (10 μM; 24 h). Immunoblots for STAT1a S727p in iBMDMs treated with IFNγ ± Veliparib (Vel.) as indicated.

: Veliparib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Jun 24;12(1):3931. [Abstract]; Veliparib (10 μM; 24 h). Bar graphs showing the relative mRNA levels upon treatment IFNγ treatment ± Veliparib (Vel.).

: Veliparib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Jun 24;12(1):3931. [Abstract]; Veliparib (10 μM; 24 h). PARP catalytic inhibition results in attenuation of NOS activity in iBMDMs. The cells were treated with IFNγ and Veliparib for 24 hours as indicated.

: Veliparib purchased from MedChemExpress. Usage Cited in: J Vet Med Sci. 2018 Nov 23;80(11):1775-1781. [Abstract]; PK-15 cells are incubated with 20 μM ABT-888 for 1 hr and subsequently infected with transmissible gastroenteritis virus (TGEV) for 36 hr. Cells are collected and then subjected to Western blot analysis for PARP-1.

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Ver todos los productos específicos de isoformas PARP:

Ver todas las isoformas

PARP PARP1 PARP2 PARP3 PARP4 TNKS1/PARP5A TNKS2/PARP5B PARP7 PARP10 PARP14 PARP15 PARP12 PARP16

Actividad biológica
Protocolo
Pureza y Documentación
Referencias
Revisión del cliente

Descripciòn

Veliparib (ABT-888) is a potent PARP inhibitor, inhibiting PARP1 and PARP2 with K_is of 5.2 and 2.9 nM, respectively^[1].

IC₅₀ & Target^[1]

PARP-2

2.9 nM (Ki)

PARP-1

5.2 nM (Ki)

Autophagy

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	133.5 3 Compound: ABT-888	Inhibition of PARP1 in human A549 cells assessed as potentiation of TMZ-mediated cytotoxicity by measuring TMZ IC50 for growth inhibition at 0.5 uM by SRB assay (Rvb TMZ IC50 = 295 uM) Inhibition of PARP1 in human A549 cells assessed as potentiation of TMZ-mediated cytotoxicity by measuring TMZ IC50 for growth inhibition at 0.5 uM by SRB assay (Rvb TMZ IC50 = 295 uM)	[PMID: 27353531]
A549	IC₅₀	133.5 3 Compound: ABT-888	Inhibition of PARP1 in human A549 cells assessed as potentiation of TMZ-mediated cytotoxicity by measuring TMZ IC50 for growth inhibition at 0.5 uM by SRB assay (Rvb TMZ IC50 = 295 uM) Inhibition of PARP1 in human A549 cells assessed as potentiation of TMZ-mediated cytotoxicity by measuring TMZ IC50 for growth inhibition at 0.5 uM by SRB assay (Rvb TMZ IC50 = 295 uM)	[PMID: 27353531]
CAPAN-1	IC₅₀	39.7 3 Compound: ABT-888	Antiproliferative activity against BRCA2 gene mutated human Capan1 cells after 72 hrs by SRB assay Antiproliferative activity against BRCA2 gene mutated human Capan1 cells after 72 hrs by SRB assay	[PMID: 24398383]
CAPAN-1	EC₅₀	>10 3 Compound: 1; ABT-888	Cytotoxicity against BRCA2-deficient human Capan1 cells Cytotoxicity against BRCA2-deficient human Capan1 cells	[PMID: 26652717]
DLD-1	IC₅₀	0.75 3 Compound: 5	Antiproliferative activity against human DLD-1 deficient in BRCA-2 cells measured after 7 days Antiproliferative activity against human DLD-1 deficient in BRCA-2 cells measured after 7 days	[PMID: 34570508]
CAPAN-1	IC₅₀	39.7 3 Compound: ABT-888	Antiproliferative activity against BRCA2 gene mutated human Capan1 cells after 72 hrs by SRB assay Antiproliferative activity against BRCA2 gene mutated human Capan1 cells after 72 hrs by SRB assay	[PMID: 24398383]
HCC1937	IC₅₀	97.16 3 Compound: ABT-888	Antiproliferative activity against BRCA1 gene mutated human HCC1937 cells after 72 hrs by SRB assay Antiproliferative activity against BRCA1 gene mutated human HCC1937 cells after 72 hrs by SRB assay	[PMID: 24398383]
Sf9	IC₅₀	1.5 1 Compound: Vel	Inhibition of human full-length N-terminal GST-tagged PARP1 expressed in baculovirus infected Sf9 insect cells using histone as substrate measured after 1 hr by horseradish peroxidase-coupled chemiluminescence assay Inhibition of human full-length N-terminal GST-tagged PARP1 expressed in baculovirus infected Sf9 insect cells using histone as substrate measured after 1 hr by horseradish peroxidase-coupled chemiluminescence assay	[PMID: 31042381]
HCT-116	IC₅₀	64 3 Compound: ABT-888	Cytotoxicity against human HCT116 cells by SRB assay Cytotoxicity against human HCT116 cells by SRB assay	[PMID: 27353531]
A549	IC₅₀	133.5 3 Compound: ABT-888	Inhibition of PARP1 in human A549 cells assessed as potentiation of TMZ-mediated cytotoxicity by measuring TMZ IC50 for growth inhibition at 0.5 uM by SRB assay (Rvb TMZ IC50 = 295 uM) Inhibition of PARP1 in human A549 cells assessed as potentiation of TMZ-mediated cytotoxicity by measuring TMZ IC50 for growth inhibition at 0.5 uM by SRB assay (Rvb TMZ IC50 = 295 uM)	[PMID: 27353531]
DLD-1	IC₅₀	0.75 3 Compound: 5	Antiproliferative activity against human DLD-1 deficient in BRCA-2 cells measured after 7 days Antiproliferative activity against human DLD-1 deficient in BRCA-2 cells measured after 7 days	[PMID: 34570508]
Jurkat	EC₅₀	160 3 Compound: ABT-888	Inhibition of PARP1 in human Jurkat cells assessed as reduction of cell viability after 96 hrs by MTS assay Inhibition of PARP1 in human Jurkat cells assessed as reduction of cell viability after 96 hrs by MTS assay	[PMID: 23850199]
DLD-1	IC₅₀	69 3 Compound: Veliparib	Cytotoxicity against human DLD-1 cells expressing BRCA2 assessed as reduction in cell proliferation incubated for 5 days by sulforhodamine B analysis Cytotoxicity against human DLD-1 cells expressing BRCA2 assessed as reduction in cell proliferation incubated for 5 days by sulforhodamine B analysis	[PMID: 37484567]
A549	IC₅₀	15.22 3 Compound: ABT-888	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38554475]
Jurkat	EC₅₀	3 3 Compound: ABT-888	Inhibition of PARP1 in human Jurkat cells assessed as reduction of cell viability after 96 hrs by MTS assay in presence of 100 uM of temozolomide Inhibition of PARP1 in human Jurkat cells assessed as reduction of cell viability after 96 hrs by MTS assay in presence of 100 uM of temozolomide	[PMID: 23850199]
DLD-1	IC₅₀	8.85 3 Compound: Veliparib	Cytotoxicity against human DLD-1 cells with BRCA2 knockout assessed as reduction in cell proliferation incubated for 5 days by sulforhodamine B analysis Cytotoxicity against human DLD-1 cells with BRCA2 knockout assessed as reduction in cell proliferation incubated for 5 days by sulforhodamine B analysis	[PMID: 37484567]
A549	IC₅₀	> 10 3 Compound: VI	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
LoVo	EC₅₀	5.94 1 Compound: 1; ABT-888	Inhibition of PARP in human LoVo cells assessed as inhibition of poly(ADP)-ribose polymerization for 30 mins by fluorescence assay Inhibition of PARP in human LoVo cells assessed as inhibition of poly(ADP)-ribose polymerization for 30 mins by fluorescence assay	[PMID: 26652717]
HCC1937	IC₅₀	97.16 3 Compound: ABT-888	Antiproliferative activity against BRCA1 gene mutated human HCC1937 cells after 72 hrs by SRB assay Antiproliferative activity against BRCA1 gene mutated human HCC1937 cells after 72 hrs by SRB assay	[PMID: 24398383]
LoVo	GI₅₀	6203 1 Compound: 1; ABT-888	Potentiation of temozolomide-induced cytotoxicity in human LoVo cells assessed as temozolomide GI50 at 0.4 uM after 5 days by Celltiter-Glo assay Potentiation of temozolomide-induced cytotoxicity in human LoVo cells assessed as temozolomide GI50 at 0.4 uM after 5 days by Celltiter-Glo assay	[PMID: 26652717]
LoVo	EC₅₀	5.94 1 Compound: 1; ABT-888	Inhibition of PARP in human LoVo cells assessed as inhibition of poly(ADP)-ribose polymerization for 30 mins by fluorescence assay Inhibition of PARP in human LoVo cells assessed as inhibition of poly(ADP)-ribose polymerization for 30 mins by fluorescence assay	[PMID: 26652717]
MDA-MB-468	EC₅₀	43 3 Compound: Veliparib	Growth inhibition of human MDA-MB-468 cells after 72 hrs by SRB assay Growth inhibition of human MDA-MB-468 cells after 72 hrs by SRB assay	[PMID: 27561983]
HCT-116	IC₅₀	64 3 Compound: ABT-888	Cytotoxicity against human HCT116 cells by SRB assay Cytotoxicity against human HCT116 cells by SRB assay	[PMID: 27353531]
Sf9	IC₅₀	< 10 1 Compound: Vel	Inhibition of human N-terminal GST-tagged PARP2 (2 to 583 residues) expressed in baculovirus infected Sf9 insect cells using histone as substrate measured after 1 hr by horseradish peroxidase-coupled chemiluminescence assay Inhibition of human N-terminal GST-tagged PARP2 (2 to 583 residues) expressed in baculovirus infected Sf9 insect cells using histone as substrate measured after 1 hr by horseradish peroxidase-coupled chemiluminescence assay	[PMID: 31042381]
Jurkat	EC₅₀	160 3 Compound: ABT-888	Inhibition of PARP1 in human Jurkat cells assessed as reduction of cell viability after 96 hrs by MTS assay Inhibition of PARP1 in human Jurkat cells assessed as reduction of cell viability after 96 hrs by MTS assay	[PMID: 23850199]
Sf9	IC₅₀	1.5 1 Compound: Vel	Inhibition of human full-length N-terminal GST-tagged PARP1 expressed in baculovirus infected Sf9 insect cells using histone as substrate measured after 1 hr by horseradish peroxidase-coupled chemiluminescence assay Inhibition of human full-length N-terminal GST-tagged PARP1 expressed in baculovirus infected Sf9 insect cells using histone as substrate measured after 1 hr by horseradish peroxidase-coupled chemiluminescence assay	[PMID: 31042381]
Jurkat	EC₅₀	3 3 Compound: ABT-888	Inhibition of PARP1 in human Jurkat cells assessed as reduction of cell viability after 96 hrs by MTS assay in presence of 100 uM of temozolomide Inhibition of PARP1 in human Jurkat cells assessed as reduction of cell viability after 96 hrs by MTS assay in presence of 100 uM of temozolomide	[PMID: 23850199]
SW-620	EC₅₀	27.1 3 Compound: Veliparib	Growth inhibition of human SW620 cells after 72 hrs by SRB assay Growth inhibition of human SW620 cells after 72 hrs by SRB assay	[PMID: 27561983]
MDA-MB-468	EC₅₀	43 3 Compound: Veliparib	Growth inhibition of human MDA-MB-468 cells after 72 hrs by SRB assay Growth inhibition of human MDA-MB-468 cells after 72 hrs by SRB assay	[PMID: 27561983]
CAPAN-1	EC₅₀	> 10000 1 Compound: 1; ABT-888	Cytotoxicity against BRCA2-deficient human Capan1 cells Cytotoxicity against BRCA2-deficient human Capan1 cells	[PMID: 26652717]
CAPAN-1	IC₅₀	39.7 3 Compound: ABT-888	Antiproliferative activity against BRCA2 gene mutated human Capan1 cells after 72 hrs by SRB assay Antiproliferative activity against BRCA2 gene mutated human Capan1 cells after 72 hrs by SRB assay	[PMID: 24398383]
MRC5	EC₅₀	>10 3 Compound: 1; ABT-888	Cytotoxicity against human MRC5 cells Cytotoxicity against human MRC5 cells	[PMID: 26652717]
DLD-1	IC₅₀	0.75 3 Compound: 5	Antiproliferative activity against human DLD-1 deficient in BRCA-2 cells measured after 7 days Antiproliferative activity against human DLD-1 deficient in BRCA-2 cells measured after 7 days	[PMID: 34570508]
SW-620	EC₅₀	27.1 3 Compound: Veliparib	Growth inhibition of human SW620 cells after 72 hrs by SRB assay Growth inhibition of human SW620 cells after 72 hrs by SRB assay	[PMID: 27561983]
DLD-1	IC₅₀	69 3 Compound: Veliparib	Cytotoxicity against human DLD-1 cells expressing BRCA2 assessed as reduction in cell proliferation incubated for 5 days by sulforhodamine B analysis Cytotoxicity against human DLD-1 cells expressing BRCA2 assessed as reduction in cell proliferation incubated for 5 days by sulforhodamine B analysis	[PMID: 37484567]
LoVo	GI₅₀	6203 1 Compound: 1; ABT-888	Potentiation of temozolomide-induced cytotoxicity in human LoVo cells assessed as temozolomide GI50 at 0.4 uM after 5 days by Celltiter-Glo assay Potentiation of temozolomide-induced cytotoxicity in human LoVo cells assessed as temozolomide GI50 at 0.4 uM after 5 days by Celltiter-Glo assay	[PMID: 26652717]
DLD-1	IC₅₀	8.85 3 Compound: Veliparib	Cytotoxicity against human DLD-1 cells with BRCA2 knockout assessed as reduction in cell proliferation incubated for 5 days by sulforhodamine B analysis Cytotoxicity against human DLD-1 cells with BRCA2 knockout assessed as reduction in cell proliferation incubated for 5 days by sulforhodamine B analysis	[PMID: 37484567]
Sf9	IC₅₀	<10 1 Compound: Vel	Inhibition of human N-terminal GST-tagged PARP2 (2 to 583 residues) expressed in baculovirus infected Sf9 insect cells using histone as substrate measured after 1 hr by horseradish peroxidase-coupled chemiluminescence assay Inhibition of human N-terminal GST-tagged PARP2 (2 to 583 residues) expressed in baculovirus infected Sf9 insect cells using histone as substrate measured after 1 hr by horseradish peroxidase-coupled chemiluminescence assay	[PMID: 31042381]
FaDu	IC₅₀	> 10 3 Compound: VI	Antiproliferative activity against human FaDu cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human FaDu cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
HCC1937	IC₅₀	97.16 3 Compound: ABT-888	Antiproliferative activity against BRCA1 gene mutated human HCC1937 cells after 72 hrs by SRB assay Antiproliferative activity against BRCA1 gene mutated human HCC1937 cells after 72 hrs by SRB assay	[PMID: 24398383]
HCT-116	IC₅₀	64 3 Compound: ABT-888	Cytotoxicity against human HCT116 cells by SRB assay Cytotoxicity against human HCT116 cells by SRB assay	[PMID: 27353531]
HGC-27	IC₅₀	16.03 3 Compound: ABT-888	Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38554475]
HH	IC₅₀	> 10 3 Compound: VI	Antiproliferative activity against human HH cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human HH cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
HL-60	IC₅₀	> 10 3 Compound: VI	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
HUVEC	IC₅₀	> 100 3 Compound: Veliparib	Inhibition of cell proliferation in HUVECs Inhibition of cell proliferation in HUVECs	[PMID: 38678823]
HeLa	IC₅₀	18.11 3 Compound: ABT-888	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38554475]
HepG2	IC₅₀	13.69 3 Compound: ABT-888	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38554475]
Jurkat	EC₅₀	160 3 Compound: ABT-888	Inhibition of PARP1 in human Jurkat cells assessed as reduction of cell viability after 96 hrs by MTS assay Inhibition of PARP1 in human Jurkat cells assessed as reduction of cell viability after 96 hrs by MTS assay	[PMID: 23850199]
Jurkat	EC₅₀	3 3 Compound: ABT-888	Inhibition of PARP1 in human Jurkat cells assessed as reduction of cell viability after 96 hrs by MTS assay in presence of 100 uM of temozolomide Inhibition of PARP1 in human Jurkat cells assessed as reduction of cell viability after 96 hrs by MTS assay in presence of 100 uM of temozolomide	[PMID: 23850199]
K562	IC₅₀	> 10 3 Compound: VI	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
LoVo	EC₅₀	5.94 1 Compound: 1; ABT-888	Inhibition of PARP in human LoVo cells assessed as inhibition of poly(ADP)-ribose polymerization for 30 mins by fluorescence assay Inhibition of PARP in human LoVo cells assessed as inhibition of poly(ADP)-ribose polymerization for 30 mins by fluorescence assay	[PMID: 26652717]
LoVo	GI₅₀	6203 1 Compound: 1; ABT-888	Potentiation of temozolomide-induced cytotoxicity in human LoVo cells assessed as temozolomide GI50 at 0.4 uM after 5 days by Celltiter-Glo assay Potentiation of temozolomide-induced cytotoxicity in human LoVo cells assessed as temozolomide GI50 at 0.4 uM after 5 days by Celltiter-Glo assay	[PMID: 26652717]
MCF7	IC₅₀	> 100 3 Compound: Veliparib	Inhibition of cell proliferation in human MCF7 cells Inhibition of cell proliferation in human MCF7 cells	[PMID: 38678823]
MDA-MB-231	IC₅₀	> 10 3 Compound: VI	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
MDA-MB-436	IC₅₀	> 100 3 Compound: Veliparib	Inhibition of cell proliferation in human MDA-MB-436 cells assessed as PARP trapping effect Inhibition of cell proliferation in human MDA-MB-436 cells assessed as PARP trapping effect	[PMID: 38678823]
MDA-MB-468	EC₅₀	43 3 Compound: Veliparib	Growth inhibition of human MDA-MB-468 cells after 72 hrs by SRB assay Growth inhibition of human MDA-MB-468 cells after 72 hrs by SRB assay	[PMID: 27561983]
MOLT-4	IC₅₀	> 10 3 Compound: VI	Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
MRC5	EC₅₀	> 10 3 Compound: 1; ABT-888	Cytotoxicity against human MRC5 cells Cytotoxicity against human MRC5 cells	[PMID: 26652717]
PC-3	IC₅₀	> 10 3 Compound: VI	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]
SW-620	EC₅₀	27.1 3 Compound: Veliparib	Growth inhibition of human SW620 cells after 72 hrs by SRB assay Growth inhibition of human SW620 cells after 72 hrs by SRB assay	[PMID: 27561983]
Sf9	IC₅₀	1.5 1 Compound: Vel	Inhibition of human full-length N-terminal GST-tagged PARP1 expressed in baculovirus infected Sf9 insect cells using histone as substrate measured after 1 hr by horseradish peroxidase-coupled chemiluminescence assay Inhibition of human full-length N-terminal GST-tagged PARP1 expressed in baculovirus infected Sf9 insect cells using histone as substrate measured after 1 hr by horseradish peroxidase-coupled chemiluminescence assay	[PMID: 31042381]
Sf9	IC₅₀	< 10 1 Compound: Vel	Inhibition of human N-terminal GST-tagged PARP2 (2 to 583 residues) expressed in baculovirus infected Sf9 insect cells using histone as substrate measured after 1 hr by horseradish peroxidase-coupled chemiluminescence assay Inhibition of human N-terminal GST-tagged PARP2 (2 to 583 residues) expressed in baculovirus infected Sf9 insect cells using histone as substrate measured after 1 hr by horseradish peroxidase-coupled chemiluminescence assay	[PMID: 31042381]
SiHa	IC₅₀	> 10 3 Compound: VI	Antiproliferative activity against human SiHa cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human SiHa cells assessed as inhibition of cell growth by MTT assay	[PMID: 38776806]

In Vitro

Veliparib (ABT-888) is also tested against SIRT2, an enzyme that also uses NAD⁺ for catalysis, and found to be inactive (>5,000 nM). The receptor profile of Veliparib is determined in a panel of 74 receptor-binding assays at a concentration of 10 μM. Veliparib displaces control-specific binding at 50% or greater at the human H₁(61%), the human 5-HT_1A (91%), and the human 5-HT₇ (84%) sites only. The IC₅₀s for these three receptors are 5.3, 1.5, and 1.2 μM, respectively^[1].
c-Met knockdown cells show 4.2- (shMet-A; 95% CI=4-4.5) or 4.6-fold (shMet-B; 95% CI=4.4-4.8) growth inhibition when treated with 60 μM Veliparib (ABT-888). When treated with 38 μM Veliparib, c-Met knockdown cells show 2- (shMet-A; 95% CI=1.5-2.5) or 1.9-fold (shMet-B; 95% CI=1.3-2.5) growth inhibition^[2].
In HaCaT cells, at 6 h post-treatment by Veliparib (ABT-888), cell viability is significantly increases under 1,000 μM sulfur mustard (SM) exposure, whereas Veliparib does not protect cell viability under 100 μM SM exposure. Moreover, the addition of Veliparib no longer shows the protective effect at 24 h post SM exposure^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Veliparib (ABT-888) is a potent inhibitor of PARP, has good oral bioavailability, can cross the blood-brain barrier in syngeneic and xenograft tumor models^[1]. In MDA-MB-231 xenograft tumor models, combination treatment (AG014699/PF-02341066 and Veliparib (ABT-888)/Foretinib) substantially reduced tumor growth compared to either inhibitor alone^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ensayo clínico

Peso molecular

244.29

Fòrmula

C₁₃H₁₆N₄O

No. CAS

912444-00-9

Appearance

Solid

Color

White to off-white

SMILES

O=C(C1=C2NC([C@@]3(NCCC3)C)=NC2=CC=C1)N

Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvente y solubilidad

In Vitro:

DMSO : ≥ 29 mg/mL (118.71 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.0935 mL	20.4675 mL	40.9350 mL
5 mM	0.8187 mL	4.0935 mL	8.1870 mL
10 mM	0.4093 mL	2.0467 mL	4.0935 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Calculadora de molaridad
Calculadora de dilución

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (8.51 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (8.51 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (8.51 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Pureza y Documentación

Purity: 99.77%

Select Batch:

Ficha de datos (283 KB) SDS (393 KB)

COA (252 KB) HNMR (278 KB) RP-HPLC (247 KB) LCMS (93 KB) Elemental Analysis Report (109 KB)

Instrucciones de manejo (2659 KB)

Referencias

[1]. Donawho CK, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007 May 1;13(9):2728-37. [Content Brief]

[2]. Du Y, et al. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med. 2016 Feb;22(2):194-201. [Content Brief]

[3]. Liu F, et al. Effects of poly (ADP-ribose) polymerase-1 (PARP-1) inhibition on sulfur mustard-induced cutaneous injuries in vitro and in vivo. PeerJ. 2016 Apr 4;4:e1890. [Content Brief]

Ensayo de quinasas ^[2]	PARP1 enzyme activity is measured by using a commercial assay kit with the exception that cell lysates containing wild-type PARP1 or PARP Y907 mutant are used in place of the PARP1 protein included with the kit. Total lysate (500 ng) is added to each reaction. The dose course of PARP inhibitor Veliparib (ABT-888) is from 0.01 to 1,000 μM. PARP enzyme activity of wild-type and mutants is determined after incubation with the substrate is measured using a plate reader^[2]. MCE no ha confirmado la precisión de estos métodos independientemente. Son solo para referencia.
Ensayo celular ^[3]	Cell viability is quantified using the Cell Counting Kit-8 (CCK-8). This assay is based on Dojindo’s highly water-soluble tetrazolium salt. WST-8 is reduced by dehydrogenases in cells to give an orange, water-soluble formazan dye. The amount of the formazan dye generated by dehydrogenases in cells is directly proportional to the number of living cells. Briefly, exponentially growing HaCaT cells are seeded in 96-well plates at a density of 10,000 cells/well. 6 h or 24 h after exposure to sulfur mustard (SM) and the administration of Veliparib, the CCK-8 reagent is added^[3. MCE no ha confirmado la precisión de estos métodos independientemente. Son solo para referencia.
Administraciòn de animales ^[2]	Mice^[2] MDA-MB-231 (0.5×10⁶), HCC1937 (2×10⁶) or MCF-7 (5×10⁶) cells are injected into the mammary fat pads of female nude (Swiss Nu/Nu) mice of 6-8 weeks of age. A1034 (0.5×10⁶) cells are injected into the mammary fat pads of female FVB/NJ mice of 6-8 weeks of age. H1993 (0.5×10⁶) cells are injected subcutaneously into the right flank of female nude (Swiss Nu/Nu) mice of 6-8 weeks of age. When the tumor volume reaches 50 mm³, PF-02341066 (5 mg/kg) and Foretinib (5 mg/kg), AG014699 (5 mg/kg) and Veliparib (25 mg/kg), dissolved in aqueous 50 mM sodium acetate, pH 4, are administered to mice five times per week as single agents or in combination for the number of days specified in the figure legend. Tumor is measured at the indicated time points, and tumor volume is calculated by the formula: π/6×length×width². For MDA-MB-231 and A1034 xenograft mouse models, mice are imaged before and after treatment using the IVIS Imaging System to assess tumor growth. Mice are injected with 100 μL of D-luciferin (15 mg/mL in PBS). MCE no ha confirmado la precisión de estos métodos independientemente. Son solo para referencia.
Referencias	[1]. Donawho CK, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007 May 1;13(9):2728-37. [Content Brief] [2]. Du Y, et al. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med. 2016 Feb;22(2):194-201. [Content Brief] [3]. Liu F, et al. Effects of poly (ADP-ribose) polymerase-1 (PARP-1) inhibition on sulfur mustard-induced cutaneous injuries in vitro and in vivo. PeerJ. 2016 Apr 4;4:e1890. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	4.0935 mL	20.4675 mL	40.9350 mL	102.3374 mL
	5 mM	0.8187 mL	4.0935 mL	8.1870 mL	20.4675 mL
	10 mM	0.4093 mL	2.0467 mL	4.0935 mL	10.2337 mL
	15 mM	0.2729 mL	1.3645 mL	2.7290 mL	6.8225 mL
	20 mM	0.2047 mL	1.0234 mL	2.0467 mL	5.1169 mL
	25 mM	0.1637 mL	0.8187 mL	1.6374 mL	4.0935 mL
	30 mM	0.1364 mL	0.6822 mL	1.3645 mL	3.4112 mL
	40 mM	0.1023 mL	0.5117 mL	1.0234 mL	2.5584 mL
	50 mM	0.0819 mL	0.4093 mL	0.8187 mL	2.0467 mL
	60 mM	0.0682 mL	0.3411 mL	0.6822 mL	1.7056 mL
	80 mM	0.0512 mL	0.2558 mL	0.5117 mL	1.2792 mL
	100 mM	0.0409 mL	0.2047 mL	0.4093 mL	1.0234 mL

Veliparib Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Veliparib912444-00-9ABT-888ABT888ABT 888PARPAutophagypoly ADP ribose polymeraseInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Nombre del producto			Requested Quantity *
Nombre del solicitante *			Saludo
Direcciòn del E-mail *			Número de teléfono *
Department			Nombre de la Organizaciòn *
City			Provincia
Country or Region *
Observaciones

Nombre del producto			Lot #
Nombre del solicitante *			Direcciòn del E-mail *
Número de teléfono			Department *
Nombre de la Organizaciòn *			Country or Region *
Observaciones

Name
E-mail *

	Sorry, but the email address you supplied was invalid.

Veliparib (Synonyms: ABT-888)

Revisión del cliente

Other Forms of Veliparib:

Veliparib Related Antibodies

49 Publications Citing Use of MCE Veliparib

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Ver todos los productos específicos de isoformas PARP:

Actividad biológica

Protocolo

Pureza y Documentación

Referencias

Revisión del cliente

Veliparib Related Antibodies

Calculadora de molaridad

Calculadora de dilución

Complete Stock Solution Preparation Table

Veliparib Related Classifications

Keywords:

Productos vistos recientemente:

Revisión del cliente

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report